References
- 1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-787.10.1038/414782a
- 2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.10.2337/diacare.16.2.434
- 3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.10.1056/NEJM199807233390404
- 4. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation. 1997;95(6):1366-1369.10.1161/01.CIR.95.6.1366
- 5. Mintz GS. Diabetic Coronary Artery Disease. JACC. 2008;52(4):263-265.10.1016/j.jacc.2008.04.020
- 6. Scognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A. Detection of Coronary Artery Disease in Asymptomatic Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2006;47(1):65-71.10.1016/j.jacc.2005.10.008
- 7. Srinivasan MP, Kamath KP, Bhat NM, et al. Severity of coronary artery disease in type 2 diabetes mellitus: Does the timing matter? Indian Heart J. 2016;68(2):158-163.10.1016/j.ihj.2015.08.004
- 8. Aronson D, Edelman ER. Revascularization for coronary artery disease in diabetes mellitus: Angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord. 2010;11(1):75-86.10.1007/s11154-010-9135-3
- 9. Wiebe J, Nef HM, Hamm CW. Current Status of Bioresorbable Scaffolds in the Treatment of Coronary Artery Disease. J Am Coll Cardiol. 2014;64(23):2541-2551.10.1016/j.jacc.2014.09.041
- 10. Pletcher MJ, Tice JA, Pignone M, McCulloch C, Callister TQ, Browner WS. What does my patient's coronary artery calcium score mean? Combining information from the coronary artery calcium score with information from conventional risk factors to estimate coronary heart disease risk. BMC Med. 2004;2:31.10.1186/1741-7015-2-31
- 11. Moses JW1, Leon MB, Popma JJ et al. Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery. N Engl J Med. 2003;349(14):1315-23.10.1056/NEJMoa035071
- 12. Wiebe J, Nef HM, Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol. 2014 Dec 16;64(23):2541-2551.10.1016/j.jacc.2014.09.041
- 13. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202.10.1016/j.jacc.2006.03.042
- 14. Onuma Y1, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011 Feb 22;123(7):779-97.10.1161/CIRCULATIONAHA.110.971606
- 15. Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J. 2007 Aug;28(16):1936-1945.10.1093/eurheartj/ehm194
- 16. Spuentrup E, Ruebben A, Mahnken A, et al. Artifact-free coronary magnetic resonance angiography and coronary vessel wall imaging in the presence of a new, metallic, coronary magnetic resonance imaging stent. Circulation. 2005;111:1019-1026.10.1161/01.CIR.0000156462.97532.8F
- 17. Verheye S, Ormiston JA, Stewart J, et al. A next-generation bioresorbable coronary scaffold system-from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. J Am Coll Cardiol Intv. 2014;7:89-99.10.1016/j.jcin.2013.07.007
- 18. Dörr O, Liebetrau C, Wiebe J, et al. Bioresorbable scaffolds for the treatment of in-stent restenosis. Heart Vessels. 2015;30(2):265-269.10.1007/s00380-013-0464-5
- 19. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring By Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain. J Am Coll Cardiol. 2007;49(3):378-402.10.1016/j.jacc.2006.10.001
- 20. Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol. 2004;43:1663-1669.10.1016/j.jacc.2003.09.068
- 21. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-1146.10.1161/01.CIR.100.10.1134
- 22. Arad Y, Newstein D, Cadet F, Roth M, Guerci AD. Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study. Arterioscler Thromb Vasc Biol. 2001;21(12):2051-2058.10.1161/hq1201.100257